Conventional medical therapy for osteoarthritis: Current state of the evidence

Research output: Contribution to journalArticle

Abstract

Purpose of review The incidence and prevalence of osteoarthritis at the knee, hip, and hand joints are rising. Knowledge about recent developments in the treatment of osteoarthritis is highly relevant to current medical and rheumatology practice. This review will highlight key findings from the published literature in the past 18 months, identified via a PubMed search, including the context for these studies, their key findings, and implications. Recent findings Main themes from the literature covered by this article include a continued focus on acetaminophen and glucosamine-chondroitin as therapeutic agents in the medical management of osteoarthritis. In addition, there is a relatively novel focus on use of adalimumab, a tumor necrosis factor inhibitor, and on strontium ranelate, in relation to outcomes of pain and structural progression in osteoarthritic joints. Summary Recent studies convey a continued focus on potential therapeutic benefit derived from a combination of glucosamine-chondroitin, and intrigue the reader with a focus on biologic therapy (i.e. tumor necrosis factor antagonist) for osteoarthritis, and with use of strontium ranelate as a newer agent with potential therapeutic benefit.

Original languageEnglish (US)
Pages (from-to)312-317
Number of pages6
JournalCurrent Opinion in Rheumatology
Volume27
Issue number3
DOIs
StatePublished - May 7 2015

Fingerprint

strontium ranelate
Osteoarthritis
Chondroitin
Glucosamine
Tumor Necrosis Factor-alpha
Hand Joints
Biological Therapy
Knee Osteoarthritis
Hip Joint
Rheumatology
Therapeutics
Acetaminophen
Knee Joint
PubMed
Joints
Pain
Incidence

Keywords

  • Clinical trial
  • Osteoarthritis
  • Pain
  • Structural progression

ASJC Scopus subject areas

  • Rheumatology
  • Medicine(all)

Cite this

Conventional medical therapy for osteoarthritis : Current state of the evidence. / Gelber, Allan.

In: Current Opinion in Rheumatology, Vol. 27, No. 3, 07.05.2015, p. 312-317.

Research output: Contribution to journalArticle

@article{d565169fde5f4300bd392e4ea847e1f1,
title = "Conventional medical therapy for osteoarthritis: Current state of the evidence",
abstract = "Purpose of review The incidence and prevalence of osteoarthritis at the knee, hip, and hand joints are rising. Knowledge about recent developments in the treatment of osteoarthritis is highly relevant to current medical and rheumatology practice. This review will highlight key findings from the published literature in the past 18 months, identified via a PubMed search, including the context for these studies, their key findings, and implications. Recent findings Main themes from the literature covered by this article include a continued focus on acetaminophen and glucosamine-chondroitin as therapeutic agents in the medical management of osteoarthritis. In addition, there is a relatively novel focus on use of adalimumab, a tumor necrosis factor inhibitor, and on strontium ranelate, in relation to outcomes of pain and structural progression in osteoarthritic joints. Summary Recent studies convey a continued focus on potential therapeutic benefit derived from a combination of glucosamine-chondroitin, and intrigue the reader with a focus on biologic therapy (i.e. tumor necrosis factor antagonist) for osteoarthritis, and with use of strontium ranelate as a newer agent with potential therapeutic benefit.",
keywords = "Clinical trial, Osteoarthritis, Pain, Structural progression",
author = "Allan Gelber",
year = "2015",
month = "5",
day = "7",
doi = "10.1097/BOR.0000000000000164",
language = "English (US)",
volume = "27",
pages = "312--317",
journal = "Current Opinion in Rheumatology",
issn = "1040-8711",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Conventional medical therapy for osteoarthritis

T2 - Current state of the evidence

AU - Gelber, Allan

PY - 2015/5/7

Y1 - 2015/5/7

N2 - Purpose of review The incidence and prevalence of osteoarthritis at the knee, hip, and hand joints are rising. Knowledge about recent developments in the treatment of osteoarthritis is highly relevant to current medical and rheumatology practice. This review will highlight key findings from the published literature in the past 18 months, identified via a PubMed search, including the context for these studies, their key findings, and implications. Recent findings Main themes from the literature covered by this article include a continued focus on acetaminophen and glucosamine-chondroitin as therapeutic agents in the medical management of osteoarthritis. In addition, there is a relatively novel focus on use of adalimumab, a tumor necrosis factor inhibitor, and on strontium ranelate, in relation to outcomes of pain and structural progression in osteoarthritic joints. Summary Recent studies convey a continued focus on potential therapeutic benefit derived from a combination of glucosamine-chondroitin, and intrigue the reader with a focus on biologic therapy (i.e. tumor necrosis factor antagonist) for osteoarthritis, and with use of strontium ranelate as a newer agent with potential therapeutic benefit.

AB - Purpose of review The incidence and prevalence of osteoarthritis at the knee, hip, and hand joints are rising. Knowledge about recent developments in the treatment of osteoarthritis is highly relevant to current medical and rheumatology practice. This review will highlight key findings from the published literature in the past 18 months, identified via a PubMed search, including the context for these studies, their key findings, and implications. Recent findings Main themes from the literature covered by this article include a continued focus on acetaminophen and glucosamine-chondroitin as therapeutic agents in the medical management of osteoarthritis. In addition, there is a relatively novel focus on use of adalimumab, a tumor necrosis factor inhibitor, and on strontium ranelate, in relation to outcomes of pain and structural progression in osteoarthritic joints. Summary Recent studies convey a continued focus on potential therapeutic benefit derived from a combination of glucosamine-chondroitin, and intrigue the reader with a focus on biologic therapy (i.e. tumor necrosis factor antagonist) for osteoarthritis, and with use of strontium ranelate as a newer agent with potential therapeutic benefit.

KW - Clinical trial

KW - Osteoarthritis

KW - Pain

KW - Structural progression

UR - http://www.scopus.com/inward/record.url?scp=84926324520&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84926324520&partnerID=8YFLogxK

U2 - 10.1097/BOR.0000000000000164

DO - 10.1097/BOR.0000000000000164

M3 - Article

C2 - 25784383

AN - SCOPUS:84926324520

VL - 27

SP - 312

EP - 317

JO - Current Opinion in Rheumatology

JF - Current Opinion in Rheumatology

SN - 1040-8711

IS - 3

ER -